Mesna

Mesna
Clinical data
Pronunciation	/ˈmɛznə/
AHFS/Drugs.com	Monograph
Pregnancy; category	AU: B1;
Routes of; administration	By mouth, intravenous
ATC code	R05CB05 (WHO) V03AF01 (WHO);
Legal status
Legal status	AU: S4 (Prescription only); UK: POM (Prescription only); US: ℞-only;
Pharmacokinetic data
Bioavailability	45–79% (by mouth)
Metabolism	Oxidised in circulation
Elimination half-life	0.36–8.3 hours
Excretion	kidney
Identifiers
	IUPAC name sodium 2-sulfanylethanesulfonate;
CAS Number	19767-45-4 ;
PubChem CID	29769;
ChemSpider	27663 ;
UNII	NR7O1405Q9;
KEGG	D01459 ;
ChEMBL	ChEMBL975 ;
CompTox Dashboard (EPA)	DTXSID1020809 ;
ECHA InfoCard	100.039.336
Chemical and physical data
Formula	C2H5NaO3S2
Molar mass	164.17 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES [Na+].[O-]S(=O)(=O)CCS;
	InChI InChI=1S/C2H6O3S2.Na/c3-7(4,5)2-1-6;/h6H,1-2H2,(H,3,4,5);/q;+1/p-1 ; Key:XOGTZOOQQBDUSI-UHFFFAOYSA-M ;
	(what is this?) (verify)

Mesna, sold under the brand name Mesnex among others, is a medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder. It is used either by mouth or injection into a vein.

Common side effects include headache, vomiting, sleepiness, loss of appetite, cough, rash, and joint pain. Serious side effects include allergic reactions. Use during pregnancy appears to be safe for the baby but this use has not been well studied. Mesna is an organosulfur compound. It works by altering the breakdown products of cyclophosphamide and ifosfamide found in the urine making them less toxic.

Mesna was approved for medical use in the United States in 1988. It is on the World Health Organization's List of Essential Medicines.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.